Overcoming Receptor Tyrosine Kinase mediated resistance to BRAF Inhibitors in metastatic melanoma, colorectal and lung cancers. [ 2013 - 2017 ]

Research Grant

Researchers: Dr Petranel Ferrao (Principal investigator) ,  Dr Gideon Bollag ,  Prof Grant Mcarthur ,  Prof Mark Shackleton

Brief description The drug Vemurafenib results in good responses in melanoma patients. However, patients become resistant to treatment. We have identified specific receptors that can cause Vemurafenib resistance, which can be overcome by combination treatment with drugs to these receptors. We will assess melanoma patient samples for expression of these receptors which will be highly beneficial for selecting combination treatments to prevent drug resistance and ensure better prolonged outcomes.

Funding Amount $AUD 574,958.86

Funding Scheme Project Grants

Notes Standard Project Grant